(PDF) P121 Clinical Value of Local Therapy in Advanced

P121 Clinical Value of Local Therapy in Advanced Crizotinib-Treated ALK-Rearranged Lung Cancer: Pattern of Failure Analyses

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.147

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.01-53 Local Treatment for Oligoprogression/Oligometastases After Failure to Crizotinib for ALK-Rearranged Stage IV Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Clinical Lung Cancer

Cancer Research

Respiratory Medicine

English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

English

Efficacy of Target Therapy With Crizotinib in a Patient With Alk-Positive Advanced Gastric Cancer

Siberian Journal of Oncology

Cancer Research

English

P1.01-35 Tumor Volume Analysis in ALK-Rearranged NSCLC Treated With Crizotinib: Identifying an Early Marker for Clinical Outcome

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Feature and Survival Outcomes of Lung Cancer With ALK Mutation Positive and Treated With Crizotinib, Single Centre Experience

Acta Oncologica Turcica

English

Feasibility of Continuing Crizotinib Therapy After RECIST-PD in Advanced Non-Small Cell Lung Cancer Patients With ALK/ROS-1 Mutations

Journal of Cancer

English

Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer

Thoracic Cancer

Respiratory Medicine

English

P071 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English